ERBB2 and neoplasm: Tumor diameters and SUVmax were significantly decreased (p < 0.001), with MRI being more sensitive in ER-positive and E-cadherin-negative patients, while PET/CT was more sensitive in those with HER-2 overexpression, Luminal-B, or proliferation rate >14% (p = 0.01).